True. I misspoke in saying that there was no dose
True. I misspoke in saying that there was no dose escalation in P1. But they escalated dose in P1 until they... didn't find adverse effects or declining/stabilizing efficacy? That's why I said the company should have addressed it in P2. And you're correct about it being a prior company/ownership that screwed that up originally, but it still stands that the lack of foresight is why we're still in purgatory. We dose escalated in P3, no reason we couldn't have done it in P2 to ensure that our P3 was correct from the get go.
Should the FDA have simply allowed 350mg? Absolutely. No question whatsoever. But we can't count on the FDA to be on our team, the company has to be its own advocate. And while the company has done that effectively on several occasions, it's always after the fact. NP got the FDA to agree to reduced requirements on this, or more lenient enrollment requirements for that... but always after we should have already been done with whatever it is we're getting fixed:
- Needing more patients in combo P3 to show statistical power? A decent high school math student could have gotten that correct the first time. So dropping to MDR-2 from MDR-3 to speed up enrollment for the additional patients doens't impress me there. Should have been negotiated correctly to begin with.
- Three months of stability for 700mg instead of six? Once again, doesn't impress me. As soon as the FDA started asking for data on safety and efficacy for 700mg - well more than six months ago - the company should have started creating the stability data to ensure that we had it ready to go if necessary, not waiting to see and creating another potential delay to the BLA.
You, and many others here, know where I stand with this drug and my investment. I'm all in, pot committed. But the accumulated small failures of our management has have worn out their welcome with me personally.
On a side note, nobody should be surprised that there's selling pressure to $0.26. That's the easy (incorrect, but easy) economic cost of the shares from the tender offer that are coming unrestricted right about... now.
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Ace Hardware Signals Expansion Through 100th Store Anyone eying the hardware retail landscape knows that Ace Hardware is not just coasting through another predictable quarter. No, this coop, fondly dubbed the helpful hardware folks, has just cranked open the doors on its 100th new store of 2026. Yep, they're charging full-throttle on their expansion strategy, determined...
Continue Reading
Legal Storm Brews for Soleno's Execs When you see Kuehn Law stepping into the ring, you know someone’s ruffling feathers. And this time, the target is Soleno Therapeutics (NASDAQ:SLNO), a name that might ring bells for tech folks dabbling in biotech. They’re under the spotlight because a federal securities lawsuit claims a questionable playbook was in the shuffle....
Continue Reading
What's Up with York Space Systems? Alright, let's dive straight into this unfolding drama. York Space Systems—fresh off their IPO in January 2026—is now neck-deep in a class action lawsuit courtesy of Robbins LLP. It's a heavy hitter for folks who put money into their stock under the assumption that it was as solid as a rock. Instead, there seems to be a soft...
Continue Reading
Unmasking the Ghosts in AI Expenses Enterprises are thrashing around in the digital ocean of AI, yet many still can't see what's draining their coffers. It's not just the savant data scientists racking up the charges; it's every automated agent chipping away at resources—unnoticed until the bill finally lands. That's where Jeen is stepping in, flipping the script on...
Continue Reading
New Frontiers in Lung Cancer Treatment Well, here's a story that rattles the cage in the oncology world. The name of the game is ivonescimab, Akeso’s latest move as they toss their hat into the already crowded yet pivotal lung cancer treatment ring. This isn't just some side hustle—they've got Phase III data pointin' straight north, figuratively casting a shadow over...
Continue Reading
Associated Banc-Corp Heads to New York for Key Financial Services Conference Wake up and smell the coffee, folks—Associated Banc-Corp (NYSE: ASB) is set to make waves at the 24th Annual Barclays Global Financial Services Conference in New York. From September 14th to 16th, seasoned execs from ASB plan to rub elbows with the industry's heavy hitters, presenting their...
Continue Reading
A Looming Need for Home-based Care Take a long, deep breath and visualize this: by 2035, America's gonna need roughly 850,000 more home care workers. That's a head-spinning figure, and if you haven't been keeping up with the projections, let me fill you in on something the Bureau of Labor Statistics threw our way. They're saying home health and personal care aides will...
Continue Reading
Garden Tech Reinvented: Enter the H5 Pro Mower Welcome to the 21st-century garden, where robotic ingenuity meets a genuine regard for nature. Folks, the Navimow H5 Pro just rolled onto the scene and it’s tearing up the old playbook of garden maintenance. It’s like blending Silicon Valley tech with Jane Goodall’s wildlife sensibilities. We're talking zero-edge...
Continue Reading
ECARX's Latest Ventures in AI-Driven Mobility ECARX is making waves with its recent announcement to integrate Tencent Cloud's WorkBuddy AI with the Flyme AIOS operating system. It's not a small tweak; it's a big leap forward in pushing AI boundaries in automobiles. If you're looking at ECARX Holdings Inc. (Nasdaq: ECX) as an investment, here's the meat and potatoes of...
Continue Reading
TVEyes Archive+ Takes Media Intelligence to New Heights Dishing out another update here, folks. TVEyes, the media intelligence powerhouse, just kicked off something that's got the potential to change the strategic media game—they call it Archive+. This tool isn’t just plundering old tapes; we're talking nearly two damn decades worth of historical broadcasts and...
Continue Reading
Top 5 Most Recently Viewed Articles
LiveOne Reports Impressive Fiscal Results LiveOne (LVO), a renowned creator-first platform specializing in music, entertainment, and technology, has disclosed its fiscal results for the first quarter. The platform recorded a revenue of $19.2 million for Q1 Fiscal 2026, despite experiencing a significant decline compared to last year’s $33.1 million. This decrease can be...
Continue Reading
Taiwan's President Calls for Unity During Budget Debate Amid ongoing budget negotiations, Taiwan's President Lai Ching-te has expressed a heartfelt plea for harmony between parties in his Lunar New Year address. This comes as the ruling Democratic Progressive Party (DPP) faces challenges following its loss of majority control in the legislature. The opposition's recent...
Continue Reading
China's Finance Ministry Announces Upcoming Press Conference BEIJING - China's finance ministry has scheduled a pivotal news conference to unveil its fiscal stimulus strategy aimed at rejuvenating the slowing economy. The announcement was made by the government's main information office, indicating the significance of this event in the context of current economic...
Continue Reading
NanoXplore Hosts a Webcast to Discuss First Quarter Results MONTREAL, October 21, 2024 – NanoXplore Inc. (“NanoXplore”) (TSX: GRA and OTCQX: NNXPF) announced a upcoming webcast focused on its financial performance for the first quarter that concluded on September 30, 2024. This informative session is scheduled for Wednesday, November 7, 2024, at 10:00 a.m. Eastern...
Continue Reading
Stewart Information Services Corporation Announces Fourth Quarter Dividend Stewart Information Services Corporation (NYSE: STC) recently made an important announcement regarding its commitment to enhancing shareholder value. The company's Board of Directors has declared a cash dividend of $0.50 per share for the fourth quarter of 2024. This notable decision reflects the...
Continue Reading